Download Sample
Add to CartGlobal Central Nervous System Disorders Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug;
Biologics, and Non Biologics.By Disease Type;
Neurovascular Diseases, CNS Trauma, Mental Health - Anxiety Disorders, Epilepsy, Mood Disorders, Psychotic Disorders, and Others, Neurodegenerative Diseases - Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Amyotrophic Lateral Sclerosis, and Others, Infectious Diseases, CNS Cancer, and Others.By Drug Class;
Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others.By Distribution Channel;
Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Central Nervous System Disorders Therapeutics Market (USD Million), 2021 - 2031
In the year 2024, the Global Central Nervous System Disorders Therapeutics Market was valued at USD 76,836.51 million. The size of this market is expected to increase to USD 113,940.98 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.8%.
The surge in mental health issues has coincided with significant disruptions to mental health services, creating substantial gaps in care that have profoundly affected the studied market during the pandemic. Many individuals continue to struggle to access the necessary care and support for both existing and newly emerging mental health conditions, posing ongoing challenges for the market in the post-pandemic era.
The increasing prevalence of central nervous system (CNS) diseases, including mental health disorders and neurodegenerative conditions, has led to a higher demand for CNS therapeutics, driving market growth. For example, a March 2023 World Health Organization (WHO) report indicates that over 55 million people worldwide have dementia, with nearly 10 million new cases reported annually. Additionally, migraines affect one billion people globally, according to a May 2022 report from Ridgecrest Regional Hospital. This rising demand has prompted both government and non-governmental organizations to allocate funds to support the development and authorization of CNS therapeutics, further fueling market expansion. For instance, Minoryx's raising of USD 55.4 million in May 2022 to advance X-linked Adrenoleukodystrophy (X-ALD) therapy exemplifies this trend.
The advent of innovative drug delivery systems is poised to drive market growth by facilitating the administration of various neurological drugs. A notable example is the strategic collaboration between Spark Therapeutics and Neurochase in January 2023, aiming to leverage Neurochase's proprietary delivery technology for selected gene therapies targeting rare CNS diseases. This collaboration underscores the potential for significant market growth through enhanced drug delivery capabilities.
The escalating burden of CNS diseases, coupled with increasing demand for CNS therapeutics and advancements in drug delivery systems, underscores the market's growth prospects. The challenges such as high research and development costs and potential adverse reactions associated with therapeutics may temper growth over the forecast period.
Global Central Nervous System Disorders Therapeutics Market Recent Developments
-
In February 2023, Sage Therapeutics, Inc. and Biogen Inc. achieved acceptance from the United States FDA for a New Drug Application (NDA) for zuranolone, intended for treating major depressive disorder (MDD) and postpartum depression (PPD).
-
In January 2023, Eisai Co., Ltd. and Biogen Inc. secured Accelerated Approval from the United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use. This medication is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody designed to target aggregated soluble and insoluble forms of amyloid beta (Aβ), aiming to treat Alzheimer's disease (AD).
Segment Analysis
The global Central Nervous System (CNS) disorders therapeutics market is divided into biologics and non-biologics, each playing a significant role in the treatment of various CNS-related diseases. Biologics, which include monoclonal antibodies, gene therapies, and vaccines, are gaining traction due to their targeted approach and reduced side effects compared to traditional drugs. Non-biologics, such as small molecule drugs, are well-established in treating a range of conditions like epilepsy, mood disorders, and neurodegenerative diseases. The continuous development of new biologic drugs is expected to accelerate the growth of this segment, although non-biologics will remain an essential part of the market due to their broader applicability and established market presence.
The disease types covered in the CNS disorders therapeutics market include neurovascular diseases, CNS trauma, mental health disorders, neurodegenerative diseases, infectious diseases, CNS cancer, and others. Neurovascular diseases, such as stroke and cerebral hemorrhage, and CNS trauma, including traumatic brain injuries, represent critical areas of treatment due to their complex nature and high demand for innovative therapies. Mental health disorders like anxiety, depression, and psychotic disorders are also prominent, driven by growing awareness and the increasing prevalence of these conditions globally. Neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis are anticipated to be major contributors to market growth as the aging population increases and the demand for effective treatments escalates.
In terms of drug class, analgesics, antidepressants, anesthetics, anti-Parkinson drugs, and anti-epileptics are key contributors to the global market. Analgesics and anesthetics are vital in managing acute and chronic pain associated with CNS trauma, while antidepressants and anti-epileptic drugs are essential for treating mental health and neurological disorders. Anti-Parkinson drugs continue to dominate the treatment of Parkinson's disease, with new advancements in therapies helping to slow disease progression. The market is also witnessing growth in the use of anti-psychotic drugs, as well as novel approaches such as gene therapies and other emerging treatments that address the underlying causes of CNS diseases.
Geographically, North America holds the largest market share, driven by advanced healthcare infrastructure, higher healthcare spending, and the presence of leading pharmaceutical companies. Europe follows closely, with a significant focus on research and development in the CNS therapeutic space. The Asia Pacific region is expected to experience rapid growth, fueled by a large patient population, increasing healthcare awareness, and improvements in healthcare infrastructure. The Middle East and Africa, along with Latin America, represent emerging markets with growing demand for affordable and effective CNS treatments. These regions are anticipated to witness steady market expansion as healthcare access improves and treatment options become more widely available.
Global Central Nervous System Disorders Therapeutics Market Analysis
In this report, the Global Central Nervous System Disorders Therapeutics Market has been segmented by Drug, Disease Type, Drug Class, Distribution Channel, and Geography.
Global Central Nervous System Disorders Therapeutics Market, Segmentation by Drug
The Global Central Nervous System Disorders Therapeutics Market has been segmented by Drug into Biologics, and Non Biologics.
The global central nervous system (CNS) disorders therapeutics market is primarily segmented based on the type of drug used for treatment. Biologics, which include a variety of therapies derived from living organisms, have seen increasing adoption in treating various CNS disorders. These biologics are designed to target specific molecular pathways involved in neurological diseases, offering more precise treatments compared to traditional drugs. As a result, biologics are being increasingly incorporated in the treatment regimens for conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis, providing hope for patients with these challenging conditions.
On the other hand, non-biologics comprise a broad range of drugs that are not derived from biological sources. These include small molecule drugs, which have been widely used in the management of CNS disorders for decades. Non-biologics are typically easier and more cost-effective to produce, making them more accessible to a larger patient population. They are commonly used to manage conditions such as depression, anxiety, and epilepsy, where traditional treatments like antidepressants and anticonvulsants are often effective in symptom management.
The segmentation of the CNS therapeutics market into biologics and non-biologics highlights the growing diversity in treatment options. Biologics, while offering novel therapies with the potential for groundbreaking results, tend to be more expensive and may have limited availability in certain regions. In contrast, non-biologics continue to play a vital role in treatment plans, given their established efficacy, lower costs, and wider accessibility. The continued development in both segments suggests a promising future for CNS therapeutics, with new innovations and advancements catering to a range of neurological conditions.
Global Central Nervous System Disorders Therapeutics Market, Segmentation by Disease Type
The Global Central Nervous System Disorders Therapeutics Market has been segmented by Disease Type into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others.
Parkinson's disease, classified under the degenerative disease segment, is anticipated to dominate the market share throughout the forecast period. This condition, characterized by its impact on the nervous system and its control over bodily functions, stems from the degeneration and eventual demise of nerve cells in both the brain and peripheral nervous system. The prominence of Parkinson's disease within the market is forecasted due to its escalating prevalence and the ongoing advancements in therapeutic research and development tailored to address its complexities.
A December 2022 report by the Parkinson's Foundation revealed a significant increase in Parkinson's disease diagnoses in the United States, with nearly 90,000 new cases annually an alarming 50% surge compared to previous estimates. Additionally, projections from the same source indicate that by 2030, the number of individuals living with Parkinson's disease in the United States is expected to soar to 1.2 million. These statistics underscore the growing burden of Parkinson's disease, amplifying the demand for therapeutic interventions and thereby propelling market growth over the forecast period.
The introduction of new products and their subsequent approvals and launches play a pivotal role in bolstering the segment's expansion. An illustrative example is Eisai Co., Ltd's launch of Equfina (safinamide mesylate) for Parkinson's disease treatment in the Asian region, excluding Japan, in February 2021. Such initiatives not only enhance the availability of treatment options but also contribute to wider product distribution across diverse geographical regions, thereby stimulating the segment's trajectory of growth over the forecast horizon.
The convergence of factors such as the escalating burden of Parkinson's disease, ongoing advancements in therapeutic innovations, and the introduction of new products, coupled with their approvals and launches, collectively underpin the anticipated growth trajectory of the market segment dedicated to addressing Parkinson's disease over the forecast period.
Global Central Nervous System Disorders Therapeutics Market, Segmentation by Drug Class
The Global Central Nervous System Disorders Therapeutics Market has been segmented Drug class into Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others.
Central nervous system (CNS) therapeutics, a diverse array of drug classes plays pivotal roles in addressing neurological and psychiatric conditions. Among these classes, analgesics, designed to alleviate pain, are essential components in managing various CNS disorders where pain is a prominent symptom. Additionally, antidepressants are indispensable in treating mood disorders such as depression and anxiety, exerting their effects by modulating neurotransmitter levels in the brain. Anesthetics also feature prominently, aiding in surgical procedures involving the CNS and ensuring patient comfort during medical interventions.
Anti-Parkinson drugs constitute another crucial category within CNS therapeutics, specifically tailored to address the symptoms of Parkinson's disease. These medications aim to mitigate motor impairments, tremors, and rigidity associated with the condition, thereby improving patients' quality of life.Anti-epileptic drugs hold significant importance in managing epileptic seizures, offering relief and seizure control to individuals grappling with epilepsy. The diversity of drug classes within CNS therapeutics underscores the multifaceted approach required to address the intricate mechanisms underlying neurological and psychiatric disorders.
Global Central Nervous System Disorders Therapeutics Market, Segmentation by Distribution channel
The Global Central Nervous System Disorders Therapeutics Market has been segmented by Distribution channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
The distribution channels play a crucial role in ensuring the accessibility and availability of medications to patients worldwide. Hospital pharmacies serve as vital hubs within healthcare institutions, offering a comprehensive range of CNS therapeutics to both inpatients and outpatients. With specialized expertise and resources, hospital pharmacies facilitate the timely provision of medications prescribed by healthcare providers, ensuring optimal management of neurological and psychiatric conditions.
Retail pharmacies represent another integral distribution channel for CNS therapeutics, providing a convenient avenue for patients to access medications within their local communities. With widespread accessibility and extended operating hours, retail pharmacies cater to the diverse needs of individuals seeking treatment for CNS disorders. Patients can obtain prescriptions, seek advice from pharmacists, and procure medications for ongoing management of their conditions, contributing to the overall continuum of care in CNS therapeutics.
In recent years, the emergence of online pharmacies has revolutionized the distribution landscape of CNS therapeutics, offering a convenient and accessible platform for patients to acquire medications remotely. Online pharmacies leverage digital technologies to facilitate the ordering, dispensing, and delivery of CNS medications, empowering patients to manage their conditions from the comfort of their homes. This digitalization trend in CNS therapeutics distribution not only enhances convenience for patients but also fosters greater access to medications, particularly for those in remote or underserved areas, thus shaping the future landscape of CNS therapeutics distribution.
Global Central Nervous System Disorders Therapeutics Market, Segmentation by Geography
In this report, the Global Central Nervous System Disorders Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Central Nervous System Disorders Therapeutics Market Share (%), by Geographical Region, 2024
North America is poised to wield significant influence over the central nervous system (CNS) therapeutics market in the coming years, driven by several key factors. Foremost among these is the rapid growth of technology within the pharmaceutical sector, facilitating advancements in drug development and fostering innovation. This technological prowess paves the way for the introduction of new therapeutics and treatment modalities tailored to address the complex needs of individuals grappling with CNS disorders. The United States and Canada, in particular, stand out as hubs of research and development, with robust infrastructures supporting a vibrant ecosystem of pharmaceutical innovation.
The escalating prevalence of CNS diseases, notably Alzheimer's dementia, underscores the pressing need for effective therapeutics within the region. According to the Alzheimer's Association's 2023 report, a staggering 6.7 million Americans aged 65 and older are projected to live with Alzheimer's dementia, a figure expected to climb due to the burgeoning geriatric population. Similarly, Canada faces its own challenges, with statistics revealing that a significant proportion of the population requires assistance with mental health issues. This growing disease burden propels demand for CNS therapeutics, prompting increased investment in research projects aimed at developing novel treatments and interventions.
In the recent initiatives and funding commitments further bolster the outlook for the CNS therapeutics market in North America. Organizations like the National Multiple Sclerosis Society are spearheading efforts to drive progress in combating neurological diseases. For instance, a substantial USD 19 million commitment in August 2022 aims to fuel research endeavors focused on halting the progression of multiple sclerosis. Additionally, regulatory approvals for new products, such as Paladin Labs Inc's carbamate for managing epilepsy, signal a conducive environment for innovation and market growth. These developments collectively underscore the region's commitment to addressing the burgeoning challenges posed by CNS disorders and highlight the potential for significant expansion in the CNS therapeutics market over the forecast period.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Central Nervous System Disorders Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Technological Advancements in Drug Development
- Rising Prevalence of CNS Disorders
-
Increased Investment in Research and Development - Increased investment in research and development (R&D) within the realm of Central Nervous System (CNS) Disorders Therapeutics serves as a driving force behind innovation and progress in the field. The growing recognition of the significant burden posed by CNS disorders, including neurodegenerative diseases like Alzheimer's and Parkinson's, as well as mental health conditions such as depression and anxiety, has spurred heightened interest and commitment from pharmaceutical companies, research institutions, and governmental agencies. This increased awareness of the unmet medical needs and the profound impact of CNS disorders on global health has catalyzed substantial investments in R&D efforts aimed at elucidating disease mechanisms, identifying novel therapeutic targets, and developing innovative treatment modalities.
Advancements in technology and scientific methodologies have expanded the possibilities for CNS therapeutics research, driving further investment in R&D initiatives. The advent of high-throughput screening techniques, omics technologies, and computational modeling approaches has revolutionized drug discovery and development processes, enabling researchers to accelerate the identification and optimization of potential drug candidates for CNS disorders. Additionally, collaborative research networks and consortia, both within the public and private sectors, have emerged to foster interdisciplinary collaborations and knowledge-sharing, further amplifying the impact of R&D investments in CNS therapeutics. This convergence of scientific innovation and collaborative endeavors underscores the pivotal role of increased investment in R&D in driving progress towards the development of effective treatments and ultimately improving outcomes for individuals affected by CNS disorders.
Restraints:
- Patent Expirations and Generic Competition
- Limited Efficacy and Safety Profiles
-
Access and Affordability Issues - Access and affordability issues pose significant restraints in the realm of Central Nervous System (CNS) Disorders Therapeutics, impeding the delivery of essential treatments to individuals in need. Limited access to healthcare services, particularly in underserved regions or low-income communities, exacerbates disparities in accessing CNS therapeutics, resulting in unequal distribution of care. Barriers such as lack of healthcare infrastructure, inadequate transportation, and geographical remoteness can hinder individuals' ability to access specialized treatments and consultations with healthcare providers, particularly for those living in rural or remote areas. These access barriers contribute to delayed diagnosis, suboptimal disease management, and poorer health outcomes for individuals grappling with CNS disorders, perpetuating inequities in healthcare access and exacerbating the burden of disease.
Affordability remains a significant challenge for many individuals seeking CNS therapeutics, particularly in regions with limited healthcare coverage or high out-of-pocket expenses. The rising costs of prescription medications, coupled with inadequate insurance coverage or lack of reimbursement policies for certain treatments, place a substantial financial burden on patients and their families. Additionally, the high costs associated with specialty drugs and innovative therapies for CNS disorders further exacerbate affordability issues, potentially leading to medication non-adherence or treatment discontinuation due to financial constraints. As a result, individuals may forego or delay necessary treatments, compromising their health outcomes and exacerbating the progression of CNS disorders, highlighting the urgent need for sustainable solutions to address access and affordability barriers in CNS therapeutics.
Opportunities:
- Digital Health Solutions
- Precision Medicine
-
Targeted Therapies - Addressing access and affordability issues in the realm of Central Nervous System (CNS) Disorders Therapeutics presents several opportunities for innovation and intervention. Leveraging telemedicine and digital health technologies can expand access to specialized care and consultations for individuals with CNS disorders, particularly those in underserved or remote areas. Virtual platforms enable remote patient monitoring, teleconsultations with healthcare providers, and digital prescriptions, facilitating timely access to diagnosis, treatment, and medication management. By harnessing the power of telehealth, healthcare organizations can bridge geographical barriers and improve healthcare access for individuals with CNS disorders, enhancing overall treatment outcomes and reducing disparities in care.
Collaborative efforts between pharmaceutical companies, healthcare providers, and governmental agencies can drive initiatives to enhance affordability and improve access to CNS therapeutics. This includes exploring innovative pricing models, such as value-based pricing or subscription-based models, to ensure cost-effective access to essential medications for individuals with CNS disorders.Advocacy for policy reforms and increased public funding for healthcare infrastructure and CNS disorder programs can help alleviate financial burdens on patients and improve affordability. By fostering multi-stakeholder partnerships and implementing policy reforms, the healthcare ecosystem can work towards sustainable solutions that enhance access to affordable CNS therapeutics, ultimately improving health outcomes and reducing the burden of CNS disorders on individuals and society as a whole.
Competitive Landscape Analysis
Key players in Global Central Nervous System Disorders Therapeutics Market include:
- Biogen
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck KGaA
- AstraZeneca
- Takeda Pharmaceutical Coompany Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson
- Pfizer Inc.
- GSK plc
- HANDA PHARMA, INC
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Dirstribution Channel
- Market Snapshot, By Region
- Global Central Nervous System Disorders Therapeutics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Technological Advancements in Drug Development
-
Rising Prevalence of CNS Disorders
-
Increased Investment in Research and Development
-
- Restraints
-
Patent Expirations and Generic Competition
-
Limited Efficacy and Safety Profiles
-
Access and Affordability Issues
-
- Opportunities
-
Digital Health Solutions
-
Precision Medicine
-
Targeted Therapies
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Central Nervous System Disorders Therapeutics Market, By Drug, 2021 - 2031 (USD Million)
- Biologics
- Non Biologics
- Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2021 - 2031 (USD Million)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others
- Neurodegenerative Diseases
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Huntington's Disease
- Amyotrophic Lateral Sclerosis
- Others
- Infectious Diseases
- CNS Cancer
- Others
- Global Central Nervous System Disorders Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
- Analgesics
- Antidepressants
- Anesthetics
- Anti-Parkinson Drugs
- Anti-Epileptics
- Others
- Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Central Nervous System Disorders Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Central Nervous System Disorders Therapeutics Market, By Drug, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Biogen
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck KGaA
- AstraZeneca
- Takeda Pharmaceutical Coompany Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson
- Pfizer Inc.
- GSK plc
- HANDA PHARMA, INC
- Company Profiles
- Analyst Views
- Future Outlook of the Market